- About Parkinson's disease
- Product profile
- Development to date
- Future development
LCT 0.017 Last updated EOD 17th January 2020
The following fact sheets provide a summary of our current business and research pipeline.
NTCELL® is expected to be indicated for restoration of function and slowing of disease progression in younger patients with early stage Parkinson’s disease experiencing reduced response to standard medical therapy – any one of the following:
- "On" time characterised by dyskinesias (or other non-motor side effects)
- "Off" time characterised by tremor, rigidity, or akinesia/bradykinesia.
- "On/Off" motor fluctuations.